A detailed history of Fmr LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 166,828 shares of RVNC stock, worth $428,747. This represents 0.0% of its overall portfolio holdings.

Number of Shares
166,828
Previous 7,628 2087.05%
Holding current value
$428,747
Previous $37,000 1056.76%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.34 - $4.73 $372,528 - $753,016
159,200 Added 2087.05%
166,828 $428,000
Q1 2024

May 13, 2024

BUY
$4.65 - $9.31 $26,951 - $53,960
5,796 Added 316.38%
7,628 $37,000
Q4 2023

Feb 13, 2024

SELL
$5.81 - $11.2 $11 Million - $21.2 Million
-1,892,275 Reduced 99.9%
1,832 $16,000
Q3 2023

Nov 13, 2023

SELL
$11.47 - $25.07 $708,937 - $1.55 Million
-61,808 Reduced 3.16%
1,894,107 $21.7 Million
Q2 2023

Aug 11, 2023

BUY
$24.7 - $37.61 $2.73 Million - $4.16 Million
110,683 Added 6.0%
1,955,915 $49.5 Million
Q1 2023

May 11, 2023

BUY
$18.36 - $35.27 $660,537 - $1.27 Million
35,977 Added 1.99%
1,845,232 $59.4 Million
Q4 2022

Feb 13, 2023

BUY
$18.32 - $30.66 $1.1 Million - $1.85 Million
60,265 Added 3.45%
1,809,255 $33.4 Million
Q3 2022

Nov 10, 2022

BUY
$14.33 - $28.47 $7.66 Million - $15.2 Million
534,672 Added 44.03%
1,748,990 $47.2 Million
Q2 2022

Aug 12, 2022

SELL
$11.52 - $20.4 $201,738 - $357,244
-17,512 Reduced 1.42%
1,214,318 $16.8 Million
Q1 2022

May 13, 2022

BUY
$12.36 - $20.31 $638,332 - $1.05 Million
51,645 Added 4.38%
1,231,830 $24 Million
Q4 2021

Feb 14, 2022

SELL
$12.46 - $27.87 $18.8 Million - $42.1 Million
-1,510,971 Reduced 56.15%
1,180,185 $19.3 Million
Q3 2021

Nov 15, 2021

SELL
$25.78 - $33.21 $106,832 - $137,622
-4,144 Reduced 0.15%
2,691,156 $75 Million
Q2 2021

Aug 13, 2021

BUY
$26.8 - $31.84 $72.2 Million - $85.8 Million
2,695,300 New
2,695,300 $79.9 Million

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Fmr LLC Portfolio

Follow Fmr LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.